September 20, the third batch of G20 enterprise conference was held, is seeking listing of our region's enterprises - Sai Sheng Pharmaceutical Co., Ltd. among the G20 scale enterprises, Sai Sheng Pharmaceuticals to turn into one of the signs of the group company. It is understood that the scale backbone enterprises are annual sales of more than 100 million yuan, outstanding contribution to industrial development, rapid growth of enterprises. So far, the development zone has been selected for the G20 list of 15 companies, accounting for more than one-third of the list of G20 companies.
During the "SARS" period, Sai Sheng Pharmaceuticals, which is famous for producing large-size injectable thymus peptide, is a high-tech enterprise in the Development Zone focusing on research and development, production and sales of biochemical injections. At present, in addition to a variety of specifications of injectable thymopeptide, we also have a number of clinical efficacy, exclusive production or the first production of the State Pharmaceutical License Number products, such as: thin chi glycopeptide injection, injectable fibrinolytic enzyme, GM1 and other products. From 2002 into the development zone, the company's annual sales revenue quadrupled from last year, the company's expansion, name change, expanding the range of products, seeking listing, and seek to complete from small and medium-sized enterprises to a group of enterprises of the magnificent turn.
Selected to the G20 can help enterprises better development, the company said, for the G20 project support measures for the introduction of independent innovation, talent, enterprise financing, major innovative varieties of clinical research, brand building and attract enterprises to Beijing development and other aspects of industrial development. At the same time, you can also enjoy the Beijing drugs into the medical insurance catalog, the implementation of quality priority in the bidding and purchasing of drugs and other initiatives to give priority to care.